Clinical Trial Update: Topical IL-1-Ra for Treatment of Corneal Neovascularization [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating a topical interleukin-1 receptor antagonist for corneal neovascularization (Phase 1/Phase 2) was terminated; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Neovascularization

Drugs mentioned

• Topical interleukin-1 receptor antagonist (anakinra)

Snippet

Sponsor: Reza Dana, MD | Conditions: Corneal Neovascularization | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-05-08